Derma Sciences to Present at Canaccord Genuity 34th Annual Growth Conference on August 14

Canaccord Growth Conference 2014

PRINCETON, N.J.--()--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announced today that Barry Wolfenson, the Company’s Group President, Advanced Wound Care and Pharmaceutical Development, will present a corporate overview and update at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 2:30 p.m. Eastern time. The conference is being held at the InterContinental Hotel in Boston.

To listen to the presentation investors may visit the investor relations section of Derma Sciences’ website at www.dermasciences.com. An archived audio of the discussion will also be available on Derma Sciences’ website for 90 days.

About Derma Sciences, Inc.

Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The company recently entered the $500 million market for skin substitute products with its licensing of AMNIOEXCEL® and AMNIOMATRIX® in the first quarter of 2014. AMNIOEXCEL® has been launched to customers and the Veterans Administration recently has included the product in its Federal Supply Schedule V797P-2000D. Derma Sciences’ MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants. Its pharmaceutical wound care products include DSC127, which is currently in Phase 3 clinical trials for the healing of diabetic foot ulcers. The drug candidate is also part of a BARDA grant program for the healing/prevention of tissue damage due to ionizing radiation exposure. The patented API peptide used in DSC127 is also in preclinical testing for scar prevention/reduction. The company also offers a full product line of traditional dressings.

For more information please visit www.dermasciences.com.

Contacts

Derma Sciences, Inc.
Barry Wolfenson, (609) 514-4744
Group President, Advanced Wound Care and Pharmaceutical Development
bwolfenson@dermasciences.com
or
LHA
Kim Sutton Golodetz, (212) 838-3777
kgolodetz@lhai.com
Or
Bruce Voss, (310) 691-7100
bvoss@lhai.com
or
Media
Spectrum Science Communications
Leticia Diaz, (202) 955-6222
ldiaz@spectrumscience.com

Sharing

Contacts

Derma Sciences, Inc.
Barry Wolfenson, (609) 514-4744
Group President, Advanced Wound Care and Pharmaceutical Development
bwolfenson@dermasciences.com
or
LHA
Kim Sutton Golodetz, (212) 838-3777
kgolodetz@lhai.com
Or
Bruce Voss, (310) 691-7100
bvoss@lhai.com
or
Media
Spectrum Science Communications
Leticia Diaz, (202) 955-6222
ldiaz@spectrumscience.com